Loading
Metastasis and Carcinoma Case Studies / Gastrointestinal Tumor Research and Treatment / Chromatin Remodeling and Cancer · Journal article
BMC Cancer · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective single-centre study of 98 SMARCA4-deficient thoracic tumour patients examined ICI efficacy in 32 advanced-stage cases (16 ICI-containing, 16 chemotherapy-only). Unadjusted progression-free survival favoured ICI therapy (median 8.6 vs 4.5 months, HR 0.36, p=0.020), but this benefit was not statistically significant after covariate adjustment and stratification, and overall survival was not improved. The authors explicitly state their treatment and biomarker findings are hypothesis-generating and require prospective validation.
Retrospective cohort study. 98 patients diagnosed with SMARCA4-deficient thoracic tumours at Shanghai Chest Hospital (May 2019–September 2023). Composition: 60 non-small cell lung cancers, 32 diffuse unilobular type, 6 neuroendocrine carcinomas. Advanced-stage comparison includes 32 non-resectable patients only.. Intervention: ICI-containing combination therapy (specific agents and regimens not detailed in abstract). Compared with: Chemotherapy alone (specific agents not detailed in abstract). n = 98. Shanghai Chest Hospital, China; single centre.
Among 98 SMARCA4-deficient thoracic tumours: 60 (61.2%) non-small cell lung cancer, 32 (32.7%) diffuse unilobular type, 6 (6.1%) neuroendocrine carcinoma In resection cohort (n reported incompletely): stage I–II versus stage III associated with DFS (HR 0.23, 95% CI 0.08–0.63, p=0.004) and OS (HR 0.11, 95% CI 0.02–0.53, p=0.006) Advanced-stage ICI-containing therapy unadjusted PFS: median 8.6 months versus 4.5 months (chemotherapy-only), HR 0.36 (95% CI 0.15–0.85, p=0.020)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
For clinicians managing advanced SMARCA4-deficient thoracic tumours, these findings suggest a potential PFS benefit with ICI-containing regimens (unadjusted HR 0.36), but the loss of statistical significance after adjustment and lack of OS improvement mean that ICI use cannot yet be recommended as standard of care. Prospective validation is needed before changing practice.
Single-centre retrospective cohort with small advanced-stage subgroups (n=16 per arm) and exploratory analyses; unadjusted PFS benefit for ICIs did not survive adjustment, and authors explicitly state findings are hypothesis-generating rather than confirmatory.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians managing advanced SMARCA4-deficient thoracic tumours, these findings suggest a potential PFS benefit with ICI-containing regimens (unadjusted HR 0.36), but the loss of statistical significance after adjustment and lack of OS improvement mean that ICI use cannot yet be recommended as standard of care. Prospective validation is needed before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Objectives SMARCA4-deficient thoracic tumor(SMARCA4-DT) is a relatively rare and highly aggressive tumors, typically associated with mutations or deletions of the SMARCA4 gene. This article aims to explore the clinical features of SMARCA4-DT patients, disease outcomes, effective prognostic indicators, and the therapeutic value of immune checkpoint inhibitors (ICIs) in advanced SMARCA4-DT patients. Methods A total of 98 cases of SMARCA4-DTs diagnosed at Shanghai Chest Hospital from May 2019 to September 2023 were selected and collected.The clinical features of all patients were analyzed, and disease-free survival (DFS) and overall survival (OS) were assessed for those with complete surgical resection. For advanced, non-resectable patients, treatment strategies were divided into a chemotherapy group and a combination therapy group, including ICIs. A statistical analysis of progression-free survival (PFS) and OS was performed to explore the therapeutic role of ICIs in advanced patients and to identify potential predictive markers. Results Among the 98 patients, 60 (61.2%) had SMARCA4-deficient non-small cell lung cancer, 32 (32.7%) had SMARCA4-dUT, and 6 (6.1%) had SMARCA4-deficient neuroendocrine carcinoma. In the resection cohort, 22 DFS events and 13 deaths occurred; stage I–II versus stage III (HR = 0.23, 95% CI: 0.08–0.63, P = 0.004) and dUT versus the carcinoma group (HR = 4.08, 95% CI: 1.67–9.98, P = 0.002) were independently associated with DFS, whereas stage I–II versus stage III (HR = 0.11, 95% CI: 0.02–0.53, P = 0.006) and NLR > 3.92 (HR = 4.20, 95% CI: 1.19–14.80, P = 0.025) were associated with OS. In the advanced-stage cohort, the ICI-containing and ICI-free chemotherapy groups each included 16 patients; the objective response rates were 50.0% and 12.5%, respectively ( P = 0.054). ICI-containing therapy was associated with longer unadjusted PFS (median, 8.6 vs. 4.5 months; HR = 0.36, 95% CI: 0.15–0.85, P = 0.020), but not OS (median, not reached vs. 15.3 months; HR = 0.41, 95% CI: 0.13–1.27, P = 0.122); after covariate adjustment and stratification by pathological group, neither PFS nor OS remained statistically significant. Among 19 unique ICI-treated patients, no statistically significant association was observed between PD-L1 expression and PFS or OS; the NLR cutoff and CDKN2A findings were exploratory and require independent validation. Conclusions Postoperative stage and pathological group were associated with DFS, whereas stage and preoperative NLR were associated with OS. In advanced disease, ICI-containing therapy was associated with longer unadjusted PFS, but the adjusted estimates were imprecise and not statistically significant; consequently, the treatment and biomarker findings should be regarded as hypothesis-generating rather than confirmatory, and prospective multicenter validation is warranted.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.